Skip Ribbon Commands
Skip to main content
Dr Nicholas Grigoropoulos

Dr Francis Grigoropoulos


Senior Consultant

Singapore General Hospital

Specialty: Haematology

Clinical Interest: Lymphoma

Clinical Appointments

  • Senior Consultant SingHealth Duke-NUS Blood Cancer Centre
  • Senior Consultant Haematology Singapore General HospitalSingapore General Hospital
  • Senior Consultant National Cancer Centre SingaporeNational Cancer Centre Singapore


Dr Nicholas obtained his medical degree from University College London in 2001. He moved to Cambridge to pursue his specialization in haematology and also completed his PhD on lymphoma genetics. He subsequently moved to Singapore. He was awarded the Transitional Award by National Medical Research Council to support his research work. Dr Nicholas has a passion is for treating and investigating blood disorders and blood cancers in particular.  He combines his clinical expertise with an intensive laboratory research interest in order to maximise the benefits of patients being treated at the SingHealth-Duke Blood Cancer Centre.


  • ​PhD, University of Cambridge, 2015
  • FRCPath, Royal College of Pathologists, 201
  • MRCP, Royal College of Physicians, 2004
  • MBBS, University College London, 2002
  • BSc, Intercalated, University College London 1998

Professional Appointments and Committee Memberships

  • Assistant Professor, Duke-NUS Graduate Medical School
  • Clinical Senior Lecturer, Yong Loo Lin School of Medicine
  • Member, SGH Research Grant Review Committee
  • Member, SingHealth Central Institutional Review Board
  • Programme Lead, Medicine ACP Research Interest Group


  • National Medical Research Council Transition Award (S$375k)
  • Duke/Duke-NUS Collaborative Pilot Grant (S$100k)
  • Khoo Pilot Award (S$30k)
  • Kay Kendall Leukaemia Fund Junior Clinical Research Fellowship (£275k)

Research Interests

  • Lymphoma and myeloma translational research


  • Kizhakeyil A, Zaini NBM, Poh ZS, Wong BHS, Loh X, Ng AS, et al. DDX3X loss is an adverse prognostic marker in diffuse large B-cell lymphoma and is associated with chemoresistance in aggressive non-Hodgkin lymphoma subtypes. Vol. 20, Molecular cancer. 2021. p. 134. 
  • Sun Y, Gao Y, Chen J, Huang L, Deng P, Chen J, et al. CREBBP cooperates with the cell cycle machinery to attenuate chidamide sensitivity in relapsed/refractory diffuse large B-cell lymphoma. Cancer Lett. 2021 Sep;521:268–80. 
  • Gong C, Krupka JA, Gao J, Grigoropoulos NF, Giotopoulos G, Asby R, et al. Sequential inverse dysregulation of the RNA helicases DDX3X and DDX3Y facilitates MYC-driven lymphomagenesis. Mol Cell. 2021 Oct;81(19):4059-4075.e11. 
  • Lim JQ, Huang D, Tang T, Tan D, Laurensia Y, Peng R-J, et al. Correction to: Whole-genome sequencing identifies responders to Pembrolizumab in relapse/refractory natural-killer/T cell lymphoma. Vol. 35, Leukemia. 2021. p. 1225. 
  • Russell J, Collins A, Fowler A, Karanth M, Saha C, Docherty S, et al. Advanced Hodgkin lymphoma in the East of England: a 10-year comparative analysis of outcomes for real-world patients treated with ABVD or escalated-BEACOPP, aged less than 60 years, compared with 5-year extended follow-up from the RATHL trial. Ann Hematol. 2021 Apr;100(4):1049–58. 
  • Ong SY, Lim JQ, Grigoropoulos N, Laurensia Y, Huang D, Chia BKH, et al. No association between ECSIT germline mutations and hemophagocytic  lymphohistiocytosis in natural killer/T-cell lymphoma. Vol. 106, Haematologica. 2021. p. 1737–9. 
  • Chen Y, Gopalakrishnan SK, Ooi M, Sultana R, Lim LH, Grigoropoulos N, et al. A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1). Vol. 11, Blood cancer journal. 2021. p. 150. 
  • Ong SY, de Mel S, Grigoropoulos NF, Chen Y, Tan YC, Tan MSY, et al. High-dose methotrexate is effective for prevention of isolated CNS relapse in diffuse large B cell lymphoma. Blood Cancer J [Internet]. 2021 Aug 12;11(8):143. Available from:
  • Lim JQ, Huang D, Tang T, Tan D, Laurensia Y, Peng R-J, et al. Whole-genome sequencing identifies responders to Pembrolizumab in relapse/refractory natural-killer/T cell lymphoma. Vol. 34, Leukemia. 2020. p. 3413–9. 
  • Lin G-W, Xu C, Chen K, Huang H-Q, Chen J, Song B, et al. Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study in multiple populations. Lancet Oncol. 2020 Feb;21(2):306–16. 
  • Phipps C, Lee YS, Ying H, Nagarajan C, Grigoropoulos N, Chen Y, et al. The impact of time from diagnosis to treatment in diffuse large B-cell lymphoma. Leuk Lymphoma. 2018 Oct;59(10):2336–41. 
  • Clipson A, Barrans S, Zeng N, Crouch S, Grigoropoulos NF, Liu H, et al. The prognosis of MYC translocation positive diffuse large B-cell lymphoma depends on the second hit. J Pathol Clin Res. 2015 Jul;1(3):125–33. 
  • Wang M, Escudero-Ibarz L, Moody S, Zeng N, Clipson A, Huang Y, et al. Somatic Mutation Screening Using Archival Formalin-Fixed, Paraffin-Embedded Tissues by Fluidigm Multiplex PCR and Illumina Sequencing. J Mol Diagn. 2015 Sep;17(5):521–32. 
  • Grigoropoulos NF, Petter R, Van ’t Veer MB, Scott MA, Follows GA. Leukaemia update. Part 2: managing patients with leukaemia in the community. BMJ. 2013 Apr;346:f1932. 
  • Grigoropoulos NF, Petter R, Van ’t Veer MB, Scott MA, Follows GA. Leukaemia update. Part 1: diagnosis and management. BMJ. 2013 Mar;346:f1660. 
  • Grigoropoulos NF, Mathur A. Stem cells in cardiac repair. Curr Opin Pharmacol. 2006 Apr;6(2):169–75. 

Research Trials

Selected clinical trials

Site PI

  • CHRONOS-4 trial of copanlisib in indolent B-cell lymphoma
  • Co-investigator in clinical trials (2008 – present, selected): 
  • CHRONOS-3 trial of copanlisib in indolent B-cell lymphoma
  • Quantum-First trial of quizartinib in AML
  • Phase II trial of the selective PI3 kinase α/β inhibitor BA80-6496
  • GS-1101, Phase 2 trial of idelalisib in chronic lymphocytic leukaemia
  • GOYA and GALLIUM phase III trials of obinutuzumab
  • Mab-CUTE, phase 3 study of subcutaneous maintenance rituximab